Aydah AlAwadhi, Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, shared on LinkedIn:
“An exciting time in 1st line HER2+ metastatic breast cancer management.
PATINA, DESTINY-Breast09 and HER2CLIMB-05 are reshaping the first-line treatment landscape, offering more options and opportunities to personalize care.
Different populations, different treatment strategies, and no head-to-head comparisons
Key factors to consider when selecting:
- Presence of brain metastases
- Hormone receptor status (HR+ vs HR−)
- Tumor burden and risk of impending visceral crisis
- Molecular profile, including PIK3CA mutation status
- Disease-free interval following adjuvant anti-HER2 therapy
- Efficacy and toxicity profiles of available regimens
- Patient comorbidities and overall clinical condition
- Patient preferences and quality-of-life considerations
This table is intended to summarize available treatment options, not to serve as a direct cross-trial comparison. Differences in trial design, treatment settings and patient populations preclude direct comparisons.”
You can also read: Daiichi Sankyo and AstraZeneca’s Enhertu Plus Pertuzumab Approved in China for First-Line HER2+ Metastatic Breast Cancer
